Keya Medical announced that it has completed a $30 Million Series C Funding Round led by IDG Capital, with participation from investors Alwin Capital, Source Code Capital, and Tasly Group.
Keya Medical announced on Aug. 13 that it has raised over $20 million in Series B+ funding.
Keya Medical announced today that it has received a strategic investment from Kunlun Wanwei Group, IDG Capital, Shanghai Guofang Parent Fund, and Yahui Capital.
On January 15, 2020, the National Medical Products Administration in China issued the registration certificate approving DeepVessel FFR for clinical use.
Keya Medical announced on September 21, 2018 that DEEPVESSEL FFR received ISO 13485:2016 certification for Medical Device and Quality Managements Systems as well as its CE Mark Certification after a series of on-site audits and evaluations by its notified body, DEKRA.
Recent Comments